American Society of Hirudotherapy

Smart Library

Faceted search across all 5 registries. Filter by registry type, evidence level, or safety domain.

Curated knowledge library: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.Reference collection: Content is historical, educational, or biographical reference material — not a clinical recommendation.

New to hirudotherapy? Start here

This library indexes the full evidence base. For orientation, begin with the core guides:

Compounds

119

Hirudin

The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Calin

Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Saratin

Anti-platelet adhesion protein blocking collagen-mediated platelet activation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Destabilase

Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Antistasin

Factor Xa inhibitor from the Mexican leech (1987) — used in early animal studies of factor Xa as a target; the DOAC drugs are synthetic and not derived from it.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Decorsin

RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Ornatin

RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hementerin

Direct fibrinogenolytic enzyme — degrades fibrinogen independently of plasmin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Ghilanten

Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Preclinical (animal)

Lefaxin

Factor Xa inhibitor with anti-inflammatory properties.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudin-PA

Hirudin variant from Hirudinaria manillensis with distinct kinetics.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirullin P18

Synthetic hirudin variant with improved oral pharmacokinetics — preclinical anticoagulant.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

LCI (Leech Carboxypeptidase Inhibitor)

Inhibitor of TAFI (thrombin-activatable fibrinolysis inhibitor) — synergizes with hirudin's anticoagulant action.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Bivalirudin

Synthetic 20-amino-acid hirudin analog — FDA-approved direct thrombin inhibitor for PCI anticoagulation ($636M peak revenue).

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Lepirudin

First-generation recombinant hirudin — FDA-approved 1998 for heparin-induced thrombocytopenia (HIT). Withdrawn 2012 by Bayer for commercial reasons.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Desirudin

Recombinant hirudin variant — FDA-approved 2003 for prophylaxis of DVT after hip replacement surgery.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Dabigatran

Oral direct thrombin inhibitor — FDA approved 2010 for stroke prevention in atrial fibrillation. Synthetic; designed from the inhibitor NAPAP, not derived from hirudin.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Argatroban

Synthetic small-molecule direct thrombin inhibitor — FDA approved 2000 for HIT, later also for PCI in patients with or at risk of HIT. Derived from arginine, not from hirudin.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Rivaroxaban

Oral Factor Xa inhibitor — FDA approved 2011. Synthetic (Bayer, oxazolidinone series); shares its target with the leech protein antistasin but is not derived from it.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Apixaban

Oral Factor Xa inhibitor — FDA approved 2012. Synthetic; shares its target with the leech protein antistasin but is not derived from it.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Edoxaban

Oral Factor Xa inhibitor — FDA approved 2015. Synthetic; shares its target with the leech protein antistasin but is not derived from it.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Eptifibatide

Cyclic heptapeptide GP IIb/IIIa receptor antagonist — FDA approved 1998. Designed from snake-venom barbourin; not derived from the leech.

Studied off-label: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.FDA-cleared regulatory context

Hementin

Direct fibrinogenolytic enzyme cleaving fibrinogen alpha-chain at unique sites — independent of plasmin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Antithrombin III binding protein

Leech-derived inhibitor that potentiates host antithrombin III activity — synergistic anticoagulation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Therostasin

Factor Xa inhibitor from Theromyzon tessulatum — Kunitz-domain analog with novel selectivity profile.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Haemadin

Picomolar-affinity thrombin inhibitor from Indian buffalo leech — distinct mechanism from hirudin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Tridegin

Factor XIIIa inhibitor — blocks fibrin cross-linking; novel mechanism distinct from hirudin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Ixodegrin (leech homolog)

Platelet GP IIb/IIIa antagonist family member — RGD-motif containing.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Destabilase Isopeptidase Activity

Isopeptidase domain of destabilase that cleaves cross-linked fibrin — distinct from lysozyme domain.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Leech Apyrase

ADP-degrading enzyme — prevents platelet aggregation by hydrolyzing ADP at bite site.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Tissue Factor Pathway Inhibitor

Inhibitor of tissue factor / Factor VIIa complex — blocks extrinsic coagulation pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Thrombomodulin-binding factor

Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Leech Ecotin-like Factor

Trypsin and Factor Xa inhibitor with broad-spectrum serine protease activity.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Bufrudin

Direct thrombin inhibitor from the Asian buffalo leech — hirudin homolog described in Hirudinaria manillensis secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Haemadipsin

Anticoagulant peptide described in the terrestrial Asian leech Haemadipsa zeylanica.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Whitmanin

Direct thrombin inhibitor homolog cataloged in the Chinese medicinal leech Whitmania pigra secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Piscicolin

Small direct thrombin inhibitor described in the fish leech Piscicola geometra secretome.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Macrobdellin

Anticoagulant peptide described in the North American medicinal leech Macrobdella decora.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Saratin-2

Isoform of saratin — collagen-binding anti-platelet protein from Hirudo medicinalis.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hementin-Like Protein (HLP-1)

Fibrinogenolytic / anti-platelet protein homologous to hementin — disrupts platelet aggregation.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

LAPP-2 (Leech Anti-Platelet Protein, Isoform 2)

Isoform of LAPP — collagen-binding inhibitor of platelet adhesion.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Leech Adhesion-Inhibitor Protein

Salivary protein blocking platelet adhesion to extracellular matrix components.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Destabilase-2

Second isoform of destabilase — lysozyme / isopeptidase activity targeting cross-linked fibrin.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Hirudinase

Alternate fibrin-cleaving enzyme reported in Hirudo medicinalis salivary secretions.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Collagenolytic Fibrinolysin

Dual-function protease degrading both fibrin clot scaffolds and collagen extracellular matrix.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Mechanistic

Theromin

Non-hirudin thrombin inhibitor from the rhynchobdellid leech Theromyzon tessulatum — highest-affinity natural inhibitor identified in a non-Hirudo species.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Saratin-3

Collagen-binding antiplatelet variant from the Hirudo medicinalis sialotranscriptome — paralog of saratin and saratin-2.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Hirudonin

Small thrombin-inhibitor peptide identified in the Hirudo medicinalis salivary transcriptome — truncated hirudin-family analog.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Gelin

Antiplatelet peptide identified in leech salivary transcriptome — inhibits platelet aggregation in vitro.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Gelin-2

Paralog of gelin identified in the Hirudo medicinalis sialotranscriptome — putative antiplatelet variant.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.In vitro

Showing first 50 of 119. Refine filters to narrow results.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Smart Library — Faceted Search Across All Registries | ASH